Nevro (NYSE:NVRO) had its target price boosted by research analysts at Leerink Swann from $146.00 to $158.00 in a research report issued on Wednesday, The Fly reports. The brokerage presently has a “positive” rating on the medical equipment provider’s stock. Leerink Swann’s price objective points to a potential upside of 21.40% from the stock’s previous close.
NVRO has been the subject of several other research reports. UBS Group increased their price target on shares of Nevro from $77.00 to $84.00 and gave the company a “sell” rating in a research report on Wednesday, January 15th. Morgan Stanley increased their price target on shares of Nevro from $125.00 to $142.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. JMP Securities raised their target price on shares of Nevro from $115.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 27th. JPMorgan Chase & Co. raised their target price on shares of Nevro from $96.00 to $130.00 and gave the stock a “neutral” rating in a research report on Wednesday. Finally, Canaccord Genuity raised shares of Nevro from a “hold” rating to a “buy” rating and raised their target price for the stock from $120.00 to $153.00 in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $121.77.
NVRO traded down $5.44 during trading on Wednesday, hitting $130.15. 787,522 shares of the stock traded hands, compared to its average volume of 423,807. The firm has a market capitalization of $4.42 billion, a P/E ratio of -38.51 and a beta of 0.46. The company has a debt-to-equity ratio of 0.91, a current ratio of 5.87 and a quick ratio of 4.54. The firm has a 50-day moving average of $131.56 and a 200 day moving average of $104.63. Nevro has a 12-month low of $42.82 and a 12-month high of $148.05.
In other news, CFO Andrew H. Galligan sold 17,718 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $120.11, for a total value of $2,128,108.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.60% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Pearl River Capital LLC purchased a new stake in shares of Nevro in the 4th quarter worth about $235,000. Geode Capital Management LLC lifted its position in Nevro by 7.0% during the 4th quarter. Geode Capital Management LLC now owns 405,732 shares of the medical equipment provider’s stock valued at $47,689,000 after acquiring an additional 26,664 shares during the period. Alliancebernstein L.P. lifted its position in Nevro by 4.5% during the 4th quarter. Alliancebernstein L.P. now owns 43,700 shares of the medical equipment provider’s stock valued at $5,136,000 after acquiring an additional 1,900 shares during the period. GQ Asset Management LLC purchased a new position in Nevro during the 4th quarter valued at about $252,000. Finally, AXA purchased a new position in Nevro during the 4th quarter valued at about $6,147,000.
Nevro Company Profile
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Read More: Why does a company issue an IPO?
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.